Work

P546. Preclinical Characterization and Phase 1 Evaluation of the Tolerability, Pharmacokinetics, and Enzyme Occupancy of MK-8189, a Novel PDE10A Inhibitor

Year: 2022

Type: conference-abstract

Source: Biological Psychiatry

DOI: 10.1016/j.biopsych.2022.02.783

Authors: Sean Smith, Jason Uslaner, Monika Kandebo, Eric Hostetler, Izzat Raheem, Mark Layton, Liza Gantert, Kerry Riffel, Christopher Cox, Sauzanne Khalilieh, Inge De Lepeleire, Guy Bormans, Marleen Depré, Jan de Hoon, Koen Van Laere

Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), KU Leuven

Language: English

Topic: Phosphodiesterase function and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4225007582

Cites:

Cited by: 2

Related to: 10